Regulators
FDA
Summary
The U.S. Food and Drug Administration is the gatekeeper for psychedelic drug development in the United States, from IND clearance through advisory committee review and any eventual approval or rejection.
Why it matters
For psychedelic therapies, the FDA is the institution that determines whether a program stays experimental, advances through trials, or reaches market. Its handling of Lykos’s midomafetamine NDA set the current regulatory tone for the sector.
Research notes
Context, reporting, and structured background for this dossier.
The FDA regulates drug approvals, INDs, NDAs, labeling, and post-market oversight in the United States. That makes it the single most important institutional gate in the U.S. psychedelic pipeline, whether the program is focused on PTSD, treatment-resistant depression, or another mental health indication.
Midomafetamine review
In June 2024, the Psychopharmacologic Drugs Advisory Committee met to review Lykos Therapeutics' NDA 215455 for midomafetamine capsules in PTSD. The official FDA meeting page and briefing package make clear that the agency treated the application as a major test case for psychedelic-assisted therapy, with attention on efficacy, trial conduct, functional unblinding, and safety oversight.
The agency later issued a Complete Response Letter instead of approval, leaving MDMA-assisted therapy without a U.S. marketing authorization. That outcome matters beyond Lykos because it reset expectations for how strong pivotal evidence, monitoring, and delivery-model controls will need to be in future psychedelic submissions.
Why the agency matters across the sector
The FDA also determines whether psychedelic programs can expand their IND footprints, move into later-stage trials, and present approval-grade evidence packages. For companies like Compass, Lykos, and others, trial design quality and regulator-facing documentation are not side details, they are the path itself.
Citations and source links
Source material used to ground or extend this dossier.
- [1] FDA.gov
Related reporting
Recent SCM reporting that overlaps this dossier’s company, program, or governance record.
- Where MAPS Is Now
After the FDA rejected Lykos' MDMA therapy application, MAPS shifted toward policy, education, and the long game.
- What Trump's Psychedelic Executive Order Actually Does
The White House order is broader than ibogaine alone, but the first wave of coverage is right to center ibogaine, veterans, faster FDA review, and a new federal funding push.
- FDA Offers Faster Review Pathway for Three Psychedelic Drug Programs
FDA says three psychedelic drug programs are getting access to the CNPV accelerated-review pathway. COMPASS has directly confirmed one award; Usona and Transcend/Otsuka have not.
Related entities
Other dossiers that help connect this page to the wider reporting record.
- Lykos Therapeutics
Lykos Therapeutics is the commercial entity that took over the MDMA-assisted therapy for PTSD approval path from MAPS and remains the focal company in the FDA midomafetamine saga.
- Compass Pathways
Compass Pathways is one of the most advanced public-company psilocybin developers, with a large Phase 3 COMP360 program in treatment-resistant depression and an FDA-authorized PTSD IND path.
- MDMA-Assisted Therapy